NEW YORK, June 9, 2017 /PRNewswire/ -- The proposed
acquisition of Albany Molecular Research Inc. ("AMRI" or the
"Company") (NASDAQ: AMRI) by affiliates Carlyle Group LP and
GTCR LLC (the "Affiliates") is the subject of an investigation by
WeissLaw LLP, a national class action and shareholders rights law
firm. On June 6, 2017, the
Company confirmed that it signed a definitive agreement under which
the Affiliates will acquire all outstanding shares of the Company
in a transaction valued at approximately $922 million, or $21.75 per share.
WeissLaw is investigating whether AMRI's Board acted to maximize
shareholder value prior to entering into the agreement.
Notably, on May 9, 2017, AMRI
reported it saw double-digit growth in first quarter of 2017.
It reported total revenue of $163.8
million, representing an increase of $58.2 million or 55% when compared to the
$105.6 million reported in the same
period of the previous year. AMRI also reported an impressive
83% increase in EBITDA. Additionally, the per-share offer
price represents a meager 9% premium over the Company's
June 5 closing price. Finally,
this deal will effectively privatize AMRI and exclude its
shareholders from the Company's continued success and future growth
prospects.
Given these facts, WeissLaw is investigating whether AMRI's
Board acted in the best interests of AMRI's public shareholders to
maximize shareholder value prior to entering into the
agreement. If you own AMRI shares and would like more
information about your rights or our investigation, or if you have
information to share with us, please contact Joshua Rubin by telephone at
(888) 593-4771 or by email at
stockinfo@weisslawllp.com.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com or fill out the
form on our website,
http://www.weisslawllp.com/albany-molecular-research-inc/
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/weisslaw-llp-the-proposed-acquisition-of-albany-molecular-research-inc-may-not-be-in-the-best-interest-of-amri-shareholders-300471747.html
SOURCE WeissLaw LLP